论文信息 - LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study - 字舞流文

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

G. Curigliano | S. Verma | S. Im | Young-Ae Park | S. Hurvitz | R. Hegg | Y. Liu | E. Hamilton | S. Kim | M. H. Kim | H. Iwata | Wei-Pang Chung | J. Cortes | E. Bako | L. Tseng | J. Cathcart | V. Petry | Cathie Chung | B. Xu | C. Lee | C. Chung